IRCM - Institut de Recherche en Cancérologie de Montpellier
Myriam Chentouf is currently working as an Ingénieur de Recherche at IRCM - Institut de Recherche en Cancérologie de Montpellier, specializing in the characterization, production, purification of antibodies, as well as the identification and selection of new therapeutic tools through Phage Display. Prior to this, Myriam was an ATER at CPID, focusing on the role of cytokines in type 2 diabetes pathogenesis. Myriam completed their Doctorat at CPBS, studying the mechanisms of action of the recombinant antibody 13B8.2 anti-CD4. Myriam completed their education at the University of Montpellier with a degree in Doctorat in Biology and Health, and at Université Marseille St Jérôme with a DESS in Biology Biotechnology.
IRCM - Institut de Recherche en Cancérologie de Montpellier
The Cancer Research Institute of Montpellier U1194 jointly operated by Inserm, University of Montpellier and Institut du Cancer de Montpellier (CLCC) 220 scientists and support personnel 17 research teams sharing 5000 m2 of lab space Excellent core facilities, many being part of the shared facilities network Montpellier BioCampus Biotech spin-offs Ground breaking research in basic and translational oncology developed in close collaboration with clinical departments and clinical research at ICM One central theme and two unifying programs : Molecular Targets and Cancer Therapy 1. Plasticity of solid tumors : from discoveries to personalized medecine 2. Therapeutic Antibodies in Cancer Treatment : Innovation, design and biological response